PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
Toronto, Ontario--(Newsfile Corp. - October 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical and technology company advancing pharmaceutical 3D printing for personalized medicine, today announced that it is building a portfolio of personalized peptide products for niche indications on its M3DICINES™ 3D-printed medicines platform, for near-term commercialization through the new U.S. peptide pathway. The first prod
Biotechnologies, Pharmaceutique
2026-10-29 10:01 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to
Biotechnologies, Pharmaceutique, Santé
2026-10-29 8:00 AM EDT | BioHarvest Sciences Inc.
Enodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic Development
Paris, France--(Newsfile Corp. - October 29, 2026) - Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Henrik Torp Nielsen as Chief Financial Officer. With nearly two decades of experience in biopharma finance and operations, Mr. Nielsen will lead Enodia's financial strategy and operations as the company advances its proprietary Sec61 platform. Enodia's approa
2026-10-29 7:20 AM EDT | Enodia Therapeutics
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls. No therapeutics exist today to treat patients that experience CRAO vision loss. Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027. Company also plans to evaluate KIO-401 in a Phase
Biotechnologies, Pharmaceutique
2026-10-29 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today announced that it is advancing multiple clinical research initiatives to expand the comparative evaluation of its blood-based TELO-MRD assay against Adaptive Biotechnologies' clonoSEQ
2026-10-29 6:30 AM EDT | Telo Genomics Corp.
Illumisoft Announces Plans with CHAIR for Canadian Hospital Research Program to Evaluate SaniLume
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") announces that it has collaborated with the Coalition for Community & Healthcare Acquired I
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-10-28 9:12 AM EDT | Illumisoft Lighting Corp.
Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th
White Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has updated the time of its conference call to discuss financial results for the third quarter ended September 30, 2026. The conference call will now be held at 8:00 A.M. ET on Thursday, November 5, 2026. The Company will report its
Biotechnologies, Soins de santé et hôpitaux
2026-10-28 8:30 AM EDT | Envoy Medical, Inc.
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
Highlights Two FDA designation applications submitted for creatine monohydrate in guanidinoacetate methyltransferase (GAMT) deficiency: Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD). First-in-class product opportunity. No FDA-approved treatment exists for GAMT deficiency. Families measure and mix high-dose creatine powder by hand, several times a day, for life. 3D printing for children. Weight
Biotechnologies, Pharmaceutique
2026-10-28 8:00 AM EDT | PharmaTher Holdings Ltd.
TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina
Highlights Definitive exclusive distribution agreement with SPORTORO d.o.o. for Croatia, Serbia and Bosnia and Herzegovina. Commercial scope covers VIVI Cap™, VIVI Epi™ and VIVI Med™, extending access across insulin pens, epinephrine auto-injectors, vials and other compatible temperature-sensitive medication formats. The agreement contemplates the initial order is to be placed and fully paid in
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-28 3:05 AM EDT | TempraMed Technologies Ltd.
Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th
White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Biotechnologies, Soins de santé et hôpitaux
2026-10-27 8:30 AM EDT | Envoy Medical, Inc.
InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed me
Biotechnologies, Pharmaceutique
2026-10-26 8:01 PM EDT | InMed Pharmaceuticals
MustGrow Announces "Fireside Chat" Webcast with Bayer AG
Saskatoon, Saskatchewan--(Newsfile Corp. - October 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") announces an upcoming webcast panel discussion with Bayer AG (BAYN) ("Bayer") featuring MustGrow's Chief Operating Officer Colin Bletsky with Ralf Glaubitz, Head of Crop Protection Product Team Biologicals at Bayer's Crop Science division. The "fireside chat" panel discussion will be broadcasted
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-10-26 7:00 AM EDT | MustGrow Biologics Corp.
Theralase Provides Bladder Cancer Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is providing an update on its Phase II Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Inva
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-10-26 7:00 AM EDT | Theralase Technologies Inc.
Therma Bright Announces up to $420,000 Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 14,000,000 common shares (the "Shares") at a price of $0.03/Share for total proceeds of up to $420,000 (the "Offering"). In accordance with the policies
Technologies, Biotechnologies, Santé
2026-10-23 8:37 PM EDT | Therma Bright Inc.
Defence Therapeutics Announces Convertible Debenture Interest Payment
Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and condi
Biotechnologies, Pharmaceutique, Santé
2026-10-23 4:15 PM EDT | Defence Therapeutics Inc.
Global Hemp Group Appoints Mickey Goldstein as Chief Financial Officer, Appoints Davidson & Company as Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to announce the appointment of Mickey Goldstein, CPA, CA, as Chief Financial Officer, effective immediately. Ms. Goldstein succeeds Christopher Cherry. Ms. Goldstein is Director, Accounting Advisory at Crowe MacKay LLP, where she provides strategic financial and advisory services to priv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Cannabis
2026-10-23 9:59 AM EDT | Global Hemp Group Inc.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units
Biotechnologies, Pharmaceutique, Santé
2026-10-22 5:24 PM EDT | PreveCeutical Medical Inc.
Envoy Medical Announces Reverse Stock Split
White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the
Biotechnologies, Soins de santé et hôpitaux
2026-10-22 8:30 AM EDT | Envoy Medical, Inc.
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design
White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("En
Biotechnologies, Soins de santé et hôpitaux
2026-10-20 8:30 AM EDT | Envoy Medical, Inc.
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025. Growing patent portfolio: 4 new global patents granted in 2026, for a total of Global distribut
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-20 7:00 AM EDT | TempraMed Technologies Ltd.